OSIMERTINIB KEY LATE-STAGE CLINICAL TRIALS

AstraZeneca remains committed to being a leader in lung cancer research.

**AURA3 TRIAL**
- **Phase III**
- Locally advanced or metastatic (Stage IIIB-IV) epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC)
- **Stage**
- **Population Characteristics**
- **Comparator Arm**
- Platinum-based doublet chemotherapy
- **Primary Endpoint**
  - Progression-free survival (PFS)
- **Secondary Endpoints**
  - Overall survival (OS) and quality of life (QoL)
- **Start Date** Q3 2014
- **PFS Readout** Q3 2016
- **Completion** Q4 2018
- **Patients** 419

**FLAURA TRIAL**
- **Phase III**
- Locally advanced or metastatic (Stage IIIB-IV) EGFRm NSCLC
- **Stage**
- **Population Characteristics**
- **Comparator Arm**
- First-generation EGFR-TKIs
- **Primary Endpoint**
  - PFS
- **Secondary Endpoints**
  - OS and QoL
- **Start Date** Q1 2015
- **PFS Readout** Q3 2017
- **Completion** Q2 2019
- **Patients** 556

**ADAURA TRIAL**
- **Phase III**
- Early or non-metastatic (Stage IIB-IHIA) EGFRm NSCLC
- **Stage**
- **Population Characteristics**
- **Comparator Arm**
- Placebo
- **Primary Endpoint**
  - Disease-free survival (DFS)
- **Secondary Endpoints**
  - DFS rate, OS, OS rate, QoL
- **Start Date** Q4 2015
- **DFS Readout** 2022
- **Completion** TBD
- **Patients** 700

*Other secondary endpoints: Objective Response Rate (ORR), Duration of Response (DoR), Disease Control Rate (DCR) and Tumor Shrinkage.  †Future dates are estimates.  ‡Other secondary endpoints: ORR, DoR, DCR, Tumor Shrinkage, Plasma Concentrations, Disease Related Symptoms, Depth of Response, Patient Reported Outcome by Therapy Satisfaction, Plasma Concentrations and Ratio, Depth of Response, Patients Reported Disease-Related Symptoms and HRQoL.*

References: